Migraine

Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine

CHICAGO, IL, Jun 09, 2007 (MARKET WIRE via COMTEX News Network)-- Endo Pharmaceuticals Inc., a wholly owned subsidiary of EndoPharmaceuticals Holdings Inc. (NASDAQ: ENDP), has presented resultsfrom a Phase III randomized, double-blind, placebo-controlledclinical trial evaluating Frova (frovatriptan succinate) 2.5 mgtablets as a six-day preventative treatment in women withdifficult-to-tre...

Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks

Nearly Twice as Many Patients Taking Trexima were Migraine FreeCompared to Placebo CHICAGO, June 08, 2007 /PRNewswire/ -- New data from two largetrials show that Trexima, when taken early, was nearly twice aseffective as placebo in eliminating all traditional migrainesymptoms at two and four hours across multiple attacks with justone tablet. The findings will be presented tomorrow at the...

NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Jun 8, 2007 - NuPathe Inc., aprivately held specialty pharmaceutical company, today announcedpositive results from an initial Phase I study of NP101SmartRelief, a novel treatment for acute migraine being developedby NuPathe. NP101 combines NuPathe's SmartRelief(TM) proprietaryiontophoretic transdermal technology with sumatriptan, the mostwidely prescri...

Merck's Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study

CHICAGO--(BUSINESS WIRE)--Jun 7, 2007 - Clinical results from aPhase II study presented for the first time at the AmericanHeadache Society (AHS) annual meeting showed that MK-0974, aninvestigational oral calcitonin gene-related peptide (CGRP)receptor antagonist, significantly improved migraine pain relieftwo hours after dosing compared to placebo, and the relief wassustained through 24 hour...

Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments

Addiction can lead to hospitalization and drug withdrawal CHICAGO, May 15, 2007 /PRNewswire/ -- A new survey of hundredsof migraine patients and physicians commissioned by the NationalHeadache Foundation and conducted by Harris Interactive shows that20 percent of migraine patients are currently taking potentiallyaddictive medications that contain barbiturates or opioids and havenot been a...

Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both Traditional and Non-traditional Migraine Symptoms

New data show efficacy across the range of migraine symptoms BOSTON, May 02, 2007 /PRNewswire/ -- While many migrainesufferers experience traditional symptoms such as nausea orsensitivity to light and sound, migraine attacks can also involvesymptoms like neck pain or sinus pain that are not traditionallyassociated with migraine headaches. New data show thatsignificantly more patients usin...

Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine Attacks

Study Results Show Individuals Reported Consistent Pain-FreeResults From Attack to Attack BOSTON, May 02, 2007 /PRNewswire/ -- Patients who suffer frommigraines frequently cite inconsistent effectiveness as a reasonfor their dissatisfaction with their medicine. New data from morethan 1,100 patients show that the investigational migraine therapyTrexima, when taken early, produced pain-free...

Addex Reports Positive Results in Phase IIa Clinical Trial With ADX10059 in Migraine

GENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharmaceuticalsannounced today the successful completion of a Phase IIa proof ofconcept trial with its lead compound ADX10059 in patients withmigraine. The study achieved its primary objective, the absence ofpain at 2 hours after dosing, with statistical significance, andalso showed trends towards improvement in pain-free status andimprovement...